|
A 24-week, multicentre, non-interventional, prospective study to describe clinical outcomes of advancing therapy with iGlarLixi in patients with T2DM sub-optimally controlled on basal insulin with or without OADs in daily practice in Saudi Arabia
|
|
|
4
|
|
|
|
REFINE-IO An Observational study in patients with unresectable hepatocellular carcinoma (uHCC) following treatment with atezolizumab plus bevacizumab (AB) or with another approved immunooncology immune checkpoint inhibitor combination in first-line.
|
|
|
4
|
|
|
|
Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi- Center, Open-Label, Single-Arm, Phase II, PET-Adaptive Study
|
|
|
2
|
|
|
|
A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1
|
|
|
3
|
|
|
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients with Congenital Hyperinsulinism
|
|
|
3
|
|
|
|
Modified Quadruple Therapy Regimen for Helicobacter pylori Eradication – A Prospective Randomized Controlled Trial
|
|
|
2
|
|
|
|
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER
|
|
|
3
|
|
|
|
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension
|
|
|
3
|
|
|
|
The effect of novel D3 use as a mouthwash in COVID-19 patients
|
|
|
3
|
|
|
|
A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya®(somapacitan) in adults with growth hormone deficiency (AGHD) under routine clinical practice
|
|
|
4
|
|
|
